Serious Events. Should there occur serious and unexpected events which, from a reasonable pharmaceutical company's point of view, would make it impossible or impracticable to pursue the commercialization of the Product, including but not limited to (i) a serious adverse event associated with the Compound and/ or the Product or (ii) infringement of any Third Party intellectual property rights by the manufacture, importation, use or sale of the Product, either Party may terminate this Agreement upon thirty (30) days' written notice.
Appears in 3 contracts
Sources: Sales, Distribution, and Development Agreement, Sales, Distribution, and Development Agreement (Abbott Laboratories), Sales, Distribution, and Development Agreement (Supergen Inc)